Patrys held its 2022 Annual General Meeting (AGM) this morning.
The past financial year has been very productive for the Company, with significant advancements in both clinical and corporate activities.
Highlights include:
- Release of new data demonstrating the ability of PAT-DX3 to cross the blood-brain barrier (BBB) in an animal model of primary brain cancer (glioblastoma multiforme, GBM).
- Data showing the applicability of deoxymab antibodies as targeting agents in antibody drug conjugates (ADCs) with improved survival in an animal model of breast cancer.
- Successful engineering run for PAT-DX1 completed in June 2022, which is being used in GLP toxicology studies.
- Award of $250,000 to Telethon Kids Institute from Clinical Accelerator fund of Cure Brain Cancer Foundation to conduct further research on potential therapeutic applications for PAT-DX1 and PAT-DX3 in the treatment of brain cancers.
- Publication of exciting research supporting a link between neutrophil extracellular traps (NETs) and therapeutic potential of PAT-DX1 in the journal Immunohorizons.
- Expansion of the executive team, with the appointment of Dr. Rebecca Tunstall as Vice President, Corporate Development
- Successfully raised $7.8 million via a placement and fully underwritten rights issue.
Interim Chairman, Michael Stork said:
“Our achievements throughout this year were made possible due to the outstanding efforts of the entire Patrys team, and our dedicated network of commercial, clinical, and academic partners. I would like to thank you all for your unwavering commitment to keeping our programs on course.”